Evoke Pharma Inc
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medi… Read more
Evoke Pharma Inc (EVOK) - Net Assets
Latest net assets as of September 2025: $3.36 Million USD
Based on the latest financial reports, Evoke Pharma Inc (EVOK) has net assets worth $3.36 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.65 Million) and total liabilities ($12.29 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.36 Million |
| % of Total Assets | 21.48% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | 103.12% |
| Growth Volatility | 79.84 |
Evoke Pharma Inc - Net Assets Trend (2011–2024)
This chart illustrates how Evoke Pharma Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Evoke Pharma Inc (2011–2024)
The table below shows the annual net assets of Evoke Pharma Inc from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $7.04 Million | +372.84% |
| 2023-12-31 | $-2.58 Million | -163.15% |
| 2022-12-31 | $4.08 Million | +14.90% |
| 2021-12-31 | $3.56 Million | +210.59% |
| 2020-12-31 | $-3.21 Million | -173.38% |
| 2019-12-31 | $4.38 Million | +8.82% |
| 2018-12-31 | $4.03 Million | +85.86% |
| 2017-12-31 | $2.17 Million | -42.82% |
| 2016-12-31 | $3.79 Million | +9.31% |
| 2015-12-31 | $3.46 Million | -62.29% |
| 2014-12-31 | $9.19 Million | -56.62% |
| 2013-12-31 | $21.18 Million | +207.75% |
| 2012-12-31 | $-19.66 Million | -11.36% |
| 2011-12-31 | $-17.65 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Evoke Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11095415700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $149.00 | 0.00% |
| Other Components | $135.83 Million | 1929.94% |
| Total Equity | $7.04 Million | 100.00% |
Evoke Pharma Inc Competitors by Market Cap
The table below lists competitors of Evoke Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Stars Microelectronics (Thailand) PCL
BK:SMT
|
$18.95 Million |
|
Aloys Inc.
KQ:297570
|
$18.95 Million |
|
Thai Rayon Public Company Limited
BK:TR
|
$18.95 Million |
|
Microtips Technology
TWO:3285
|
$18.95 Million |
|
Abko Co. Ltd
KQ:129890
|
$18.95 Million |
|
NFON AG
XETRA:NFN
|
$18.94 Million |
|
01 Quantum Inc.
F:DFK0
|
$18.94 Million |
|
INNOVANA
NSE:INNOVANA
|
$18.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Evoke Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -2,579,537 to 7,038,010, a change of 9,617,547.
- Net loss of 5,352,194 reduced equity.
- Share repurchases of 191 reduced equity.
- New share issuances of 6,718,211 increased equity.
- Other factors increased equity by 8,251,721.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.35 Million | -76.05% |
| Share Repurchases | $191.00 | -0.0% |
| Share Issuances | $6.72 Million | +95.46% |
| Other Changes | $8.25 Million | +117.25% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Evoke Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.61x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-2235.86 | $28.10 | x |
| 2012-12-31 | $-2282.79 | $28.10 | x |
| 2013-12-31 | $1288.21 | $28.10 | x |
| 2014-12-31 | $219.34 | $28.10 | x |
| 2015-12-31 | $76.93 | $28.10 | x |
| 2016-12-31 | $58.41 | $28.10 | x |
| 2017-12-31 | $20.93 | $28.10 | x |
| 2018-12-31 | $34.91 | $28.10 | x |
| 2019-12-31 | $28.29 | $28.10 | x |
| 2020-12-31 | $-18.16 | $28.10 | x |
| 2021-12-31 | $15.91 | $28.10 | x |
| 2022-12-31 | $15.59 | $28.10 | x |
| 2023-12-31 | $-9.26 | $28.10 | x |
| 2024-12-31 | $3.69 | $28.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Evoke Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -76.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -52.22%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 2.49x
- Recent ROE (-76.05%) is above the historical average (-158.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-635.81K |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-51.59K |
| 2013 | -13.39% | 0.00% | 0.00x | 1.18x | $-4.95 Million |
| 2014 | -144.17% | 0.00% | 0.00x | 1.67x | $-14.17 Million |
| 2015 | -349.83% | 0.00% | 0.00x | 2.75x | $-12.47 Million |
| 2016 | -283.78% | 0.00% | 0.00x | 2.45x | $-11.13 Million |
| 2017 | -564.68% | 0.00% | 0.00x | 3.67x | $-12.45 Million |
| 2018 | -187.96% | 0.00% | 0.00x | 1.41x | $-7.97 Million |
| 2019 | -162.01% | 0.00% | 0.00x | 1.46x | $-7.53 Million |
| 2020 | 0.00% | -57144.53% | 0.00x | 0.00x | $-12.83 Million |
| 2021 | -240.16% | -527.66% | 0.15x | 2.97x | $-8.89 Million |
| 2022 | -201.34% | -327.83% | 0.21x | 2.90x | $-8.63 Million |
| 2023 | 0.00% | -150.41% | 0.73x | 0.00x | $-7.53 Million |
| 2024 | -76.05% | -52.22% | 0.59x | 2.49x | $-6.06 Million |
Industry Comparison
This section compares Evoke Pharma Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Evoke Pharma Inc (EVOK) | $3.36 Million | 0.00% | 3.65x | $18.95 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |